Terms: = Uterine cancer AND BRD4, O60885, 23476, ENSG00000141867, HUNKI, CAP, MCAP AND Prognosis
14 results:
1. HER-2 overexpression in female genital tract clear cell carcinomas: Evaluation of different scoring guidelines, clinicopathological features and prognostic impact.
Edjtemaei R; Nili F; Jahanzad I; Ameli F; Ghasemi D
Ann Diagn Pathol; 2023 Oct; 66():152184. PubMed ID: 37543027
[TBL] [Abstract] [Full Text] [Related]
2. Folate receptor alpha is widely expressed and a potential therapeutic target in uterine and ovarian carcinosarcoma.
Saito A; Nishikawa T; Yoshida H; Mizoguchi C; Kitadai R; Yamamoto K; Yazaki S; Kojima Y; Ishikawa M; Kato T; Yonemori K
Gynecol Oncol; 2023 Sep; 176():115-121. PubMed ID: 37506533
[TBL] [Abstract] [Full Text] [Related]
3. Gynecological cancer prognosis using machine learning techniques: A systematic review of the last three decades (1990-2022).
Sheehy J; Rutledge H; Acharya UR; Loh HW; Gururajan R; Tao X; Zhou X; Li Y; Gurney T; Kondalsamy-Chennakesavan S
Artif Intell Med; 2023 May; 139():102536. PubMed ID: 37100507
[TBL] [Abstract] [Full Text] [Related]
4. HER2+ endometrioid endometrial cancer possesses distinct molecular and immunologic features associated with a more active immune microenvironment and worse prognosis.
Bruce SF; Wu S; Ribeiro JR; Farrell A; Oberley MJ; Winer I; Erickson BK; Klc T; Jones NL; Thaker PH; Powell MA
Gynecol Oncol; 2023 May; 172():98-105. PubMed ID: 37003074
[TBL] [Abstract] [Full Text] [Related]
5. The brd4 inhibitor JQ1 suppresses tumor growth by reducing c-Myc expression in endometrial cancer.
Pang Y; Bai G; Zhao J; Wei X; Li R; Li J; Hu S; Peng L; Liu P; Mao H
J Transl Med; 2022 Jul; 20(1):336. PubMed ID: 35902869
[TBL] [Abstract] [Full Text] [Related]
6. brd4 inhibition sensitizes cervical cancer to radiotherapy by attenuating DNA repair.
Ni M; Li J; Zhao H; Xu F; Cheng J; Yu M; Ke G; Wu X
Oncogene; 2021 Apr; 40(15):2711-2724. PubMed ID: 33712705
[TBL] [Abstract] [Full Text] [Related]
7. HER2 testing of gynecologic carcinosarcomas: tumor stratification for potential targeted therapy.
Rottmann D; Snir OL; Wu X; Wong S; Hui P; Santin AD; Buza N
Mod Pathol; 2020 Jan; 33(1):118-127. PubMed ID: 31477811
[TBL] [Abstract] [Full Text] [Related]
8. Comparison of Different Scoring Systems in the Assessment of Estrogen Receptor Status for Predicting prognosis in Endometrial cancer.
Wang Y; Ma X; Wang Y; Liu Y; Liu C
Int J Gynecol Pathol; 2019 Mar; 38(2):111-118. PubMed ID: 29406446
[TBL] [Abstract] [Full Text] [Related]
9. [Correlation between estrogen receptor status and clinicopathologic parameters in endometrial cancer: a comparative study by immunohistochemistry using different scoring systems].
Wang Y; Ma XL; Xi CG; Lin J; Ren CX; Liu CR
Zhonghua Bing Li Xue Za Zhi; 2013 Aug; 42(8):509-14. PubMed ID: 24246914
[TBL] [Abstract] [Full Text] [Related]
10. Cell signaling in endometrial carcinoma: phosphorylated 4E-binding protein-1 expression in endometrial cancer correlates with aggressive tumors and prognosis.
Castellvi J; Garcia A; Ruiz-Marcellan C; Hernández-Losa J; Peg V; Salcedo M; Gil-Moreno A; Ramon y Cajal S
Hum Pathol; 2009 Oct; 40(10):1418-26. PubMed ID: 19428047
[TBL] [Abstract] [Full Text] [Related]
11. Adjuvant chemotherapy as treatment of high-risk stage I and II endometrial cancer.
Aoki Y; Watanabe M; Amikura T; Obata H; Sekine M; Yahata T; Fujita K; Tanaka K
Gynecol Oncol; 2004 Aug; 94(2):333-9. PubMed ID: 15297170
[TBL] [Abstract] [Full Text] [Related]
12. Effective treatment of stage I uterine papillary serous carcinoma with high dose-rate vaginal apex radiation (192Ir) and chemotherapy.
Turner BC; Knisely JP; Kacinski BM; Haffty BG; Gumbs AA; Roberts KB; Frank AH; Peschel RE; Rutherford TJ; Edraki B; Kohorn EI; Chambers SK; Schwartz PE; Wilson LD
Int J Radiat Oncol Biol Phys; 1998 Jan; 40(1):77-84. PubMed ID: 9422561
[TBL] [Abstract] [Full Text] [Related]
13. Gynecological malignancies.
Schaebler DL; Schilder RJ; Young RC
Cancer Chemother Biol Response Modif; 1996; 16():564-91. PubMed ID: 8639401
[TBL] [Abstract] [Full Text] [Related]
14. [Chemotherapy of uterine endometrial cancer].
Hayakawa S; Sato S; Takano T; Wagazuma S; Yajima A
Gan To Kagaku Ryoho; 1995 Aug; 22(9):1169-75. PubMed ID: 7661568
[TBL] [Abstract] [Full Text] [Related]
